BB Biotech AG
BB Biotech AG is an equity fund launched and managed by Bellevue Asset Management AG. The fund invests in the public equity markets across the globe. It primarily invests in stocks of companies that are engaged in medications and diagnostics based on modern biotechnology. The fund employs a fundamental analysis to create its portfolio. BB Biotech AG was formed on November 09, 1993 and is domicile… Read more
Market Cap & Net Worth: BB Biotech AG (BION)
BB Biotech AG (SW:BION) has a market capitalization of $2.78 Billion (CHF2.54 Billion) as of March 18, 2026. Listed on the SW stock exchange, this Switzerland-based company holds position #37552 globally and #132 in its home market, demonstrating a 1.88% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying BB Biotech AG's stock price CHF46.10 by its total outstanding shares 55149250 (55.15 Million).
BB Biotech AG Market Cap History: 2015 to 2026
BB Biotech AG's market capitalization history from 2015 to 2026. Data shows growth from $2.11 Billion to $2.78 Billion (3.67% CAGR).
BB Biotech AG Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how BB Biotech AG's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
19.10x
BB Biotech AG's market cap is 19.10 times its annual revenue
1742.66x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
28.09x
BB Biotech AG's market cap is 28.09 times its annual earnings
0.11x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $2.11 Billion | $659.23 Million | $652.82 Million | 3.21x | 3.24x |
| 2016 | $2.12 Billion | $-796.45 Million | -$802.07 Million | -2.66x | N/A |
| 2017 | $2.61 Billion | $693.05 Million | $687.50 Million | 3.77x | 3.80x |
| 2018 | $2.48 Billion | $-465.75 Million | -$471.34 Million | -5.32x | N/A |
| 2019 | $3.07 Billion | $685.24 Million | $677.43 Million | 4.49x | 4.54x |
| 2020 | $3.67 Billion | $699.23 Million | $691.17 Million | 5.24x | 5.31x |
| 2021 | $3.97 Billion | $-396.22 Million | -$404.81 Million | -10.03x | N/A |
| 2022 | $3.01 Billion | $-351.23 Million | -$357.81 Million | -8.57x | N/A |
| 2023 | $2.47 Billion | $35.00K | -$206.61 Million | 70440.77x | N/A |
| 2024 | $2.13 Billion | $111.63 Million | $75.90 Million | 19.10x | 28.09x |
Competitor Companies of BION by Market Capitalization
Companies near BB Biotech AG in the global market cap rankings as of March 18, 2026.
Key companies related to BB Biotech AG by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #158 globally with a market cap of $118.01 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.58 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #158 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $118.01 Billion | $466.10 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.58 Billion | $756.91 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
BB Biotech AG Historical Marketcap From 2015 to 2026
Between 2015 and today, BB Biotech AG's market cap moved from $2.11 Billion to $ 2.78 Billion, with a yearly change of 3.67%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | CHF2.78 Billion | +2.56% |
| 2025 | CHF2.71 Billion | +26.98% |
| 2024 | CHF2.13 Billion | -13.52% |
| 2023 | CHF2.47 Billion | -18.05% |
| 2022 | CHF3.01 Billion | -24.29% |
| 2021 | CHF3.97 Billion | +8.36% |
| 2020 | CHF3.67 Billion | +19.31% |
| 2019 | CHF3.07 Billion | +23.97% |
| 2018 | CHF2.48 Billion | -5.11% |
| 2017 | CHF2.61 Billion | +23.14% |
| 2016 | CHF2.12 Billion | +0.33% |
| 2015 | CHF2.11 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of BB Biotech AG was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $2.78 Billion USD |
| MoneyControl | $2.78 Billion USD |
| MarketWatch | $2.78 Billion USD |
| marketcap.company | $2.78 Billion USD |
| Reuters | $2.78 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.